Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's...
Thu Apr 04, 2019 19:00
INCHEON, South Korea & VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CD20?src=hash" target="_blank"gt;#CD20lt;/agt;--Celltrion and iProgen Biotech announced partnership for the development of novel ADCs against validated antibody targets, including HER2 and CD20.
04:51
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that interim results describing clinical outcomes for pediatric patients treated using the RECELL® System were presented at the American Burn Association (ABA) 51st Annual Meeting in Las Vegas by Jeffrey Carter, MD, FACS University Medical Center New Orleans Burn Center and LSU Health New Orleans School of Medicine. Patients enrolled in the Investig
03:00
SUMMIT, Nueva Jersey--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG), ha anunciado que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha adoptado opiniones positivas sobre dos regímenes triples basados en los medicamentos IMiD® patentados por Celgene: REVLIMID (lenalidomida) e IMNOVID (pomalidomida). En concreto, el CHMP ha recomendado la aprobación de una indicación ampliada de REVLIMID como terapia de combinación con bortezomib y dexametasona (
Fri Apr 05, 2019 23:31
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) a annoncé que le comité des médicaments à usage humain (CHMP) de l'Agence Européenne des Médicaments (EMA) a adopté des avis favorables pour deux triplettes à base de deux IMIDs® de Celgene : REVLIMID® (lénalidomide) et IMNOVID® (pomalidomide), dans le traitement du myélome multiple. Le CHMP a recommandé l'approbation d'une extension d'indication pour REVLIMID® en association avec le bortézomib et la dexaméthasone (RVd) pour le tr
Fri Apr 05, 2019 23:23
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that Robert K. Zeldin, M.D., Chief Medical Officer, is no longer employed by the company, as of today. The company has begun an executive search for his replacement. "We thank Robert for his contributions to the Company over the last 9 months and wish him the best in his fut
Fri Apr 05, 2019 23:01
DUBLIN--(BUSINESS WIRE)--The "Anorexia Nervosa Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. Anorexia Nervosa Global Clinical Trials Review, H2, 2018 provides an overview of Anorexia Nervosa clinical trials scenario. This report provides top line data relating to the clinical trials on Anorexia Nervosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report
Fri Apr 05, 2019 18:00
DUBLIN--(BUSINESS WIRE)--The "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2018" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in
Fri Apr 05, 2019 17:50
DUBLIN--(BUSINESS WIRE)--The "Anterior Uveitis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. Anterior Uveitis Global Clinical Trials Review, H2, 2018" provides an overview of Anterior Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Anterior Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report
Fri Apr 05, 2019 17:24
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta
Fri Apr 05, 2019 16:28
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for instillation, an investigational formulation for the primary non-surgical treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). The analysis, which discusses the minimally invasive chemoablation approach
Fri Apr 05, 2019 16:12
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Descovy® (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection among individuals who are HIV-negative and at risk for HIV. A Priority Review voucher was submitted with the filing, le
Fri Apr 05, 2019 15:30
DUBLIN--(BUSINESS WIRE)--The "Ragweed Pollen Allergy - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Ragweed Pollen Allergy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ragweed Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological
Fri Apr 05, 2019 15:21
DUBLIN--(BUSINESS WIRE)--The "Ocular Hypertension - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Ocular Hypertension - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological actio
Fri Apr 05, 2019 15:11
DUBLIN--(BUSINESS WIRE)--The "Becker Muscular Dystrophy - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Becker Muscular Dystrophy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive
Fri Apr 05, 2019 15:07
BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell will present an overview of the company at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019.
Fri Apr 05, 2019 15:01
LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24LIVN&src=ctag" target="_blank"gt;$LIVNlt;/agt;--LivaNova today announced preliminary unaudited revenue results for the quarter ended March 31, 2019.
Fri Apr 05, 2019 15:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has priced its concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to 1,951,844 shares of its common stock, at a combined price to the public of $7.50 per common share and accompanying Class A warrant and (ii) 666 shares of its Series A conv
Fri Apr 05, 2019 14:15
PALM SPRINGS, Californië & SCHLIEREN, Zwitserland--(BUSINESS WIRE)--Klinische onderzoekers kunnen binnenkort duizenden eiwitten uit patiëntweefsels direct meten en kwantificeren in klinische proeven met behulp van de volgende generatie labelvrije proteomics technologie ontwikkeld door Biognosys, een Zwitserse proteomics bedrijf. Dit werd voorgesteld door een presentatie van een gezamenlijke studie onder leiding van Dr. Axel Ducret (F. Hoffmann-La Roche Ltd) op de MSACL 2019 conferentie (Mass...
Fri Apr 05, 2019 10:49
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced health economic data projecting that use of the RECELL System to treat patients with severe burns could save a major U.S. burn center up to USD $28 million annually compared to treatment with the standard of care. The health economic results were presented at the American Burn Association (ABA) 51st Annual Meeting in Las Vegas by Kevin Foster, MD,...
Fri Apr 05, 2019 02:19
OSAKA, Japan, AMSTERDAM und FLORHAM PARK, New Jersey--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Hauptsitz: Osaka, Japan; President und CEO: Isao Teshirogi, Ph.D.), Shionogi B.V. und Shionogi Inc., das europäische und das US-amerikanische Tochterunternehmen von Shionogi & Co., Ltd, („Shionogi") kündigten heute zwölf Präsentationen im Rahmen des European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) an, der vom 13. bis 16. April 2019 in Amsterdam stattfindet. Acht Poster
Fri Apr 05, 2019 01:27
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it is offering to sell, subject to market and other conditions, (i) shares of its common stock and Class A warrants to purchase common stock, and (ii) shares of its Series A convertible preferred stock and Class A warrants to purchase common stock, in two concurrent but separate underwritten public offerings. The offerings a
Thu Apr 04, 2019 23:18
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a systemic muscle agent the company had been studying in a Phase 1 healthy volunteer trial for the potential treatment of neuromuscular disorders. "Although ACE-2494 showed promising early signs of target engagement in our r
Thu Apr 04, 2019 23:05
DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees. The restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with th
Thu Apr 04, 2019 23:05
ROCKVILLE, Md.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/allergies?src=hash" target="_blank"gt;#allergieslt;/agt;--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C.
Thu Apr 04, 2019 23:05
NEW YORK--(BUSINESS WIRE)--45 Leading Global Societies and 90 World-Renowned Experts to Gather in New York City at the 4th WCITD
Thu Apr 04, 2019 22:40
DANVERS, Massachusetts--(BUSINESS WIRE)--In dieser Woche vor drei Jahren erhielt Abiomed (NASDAQ: ABMD) für seine Impella-Herzpumpe die FDA PMA-Zulassung zur Behandlung von kardiogenem Schock bei AMI. Zum Zeitpunkt der FDA PMA-Zulassung von Impella betrug die Überlebensrate bis zur Explantation bei kardiogenem Schock laut der Impella Quality Assurance (IQ) Database in den Vereinigten Staaten 51 %.1 Heute tragen Impella-Herzpumpen in Kombination mit Best Practices, wie beispielsweise der Einsatz
Thu Apr 04, 2019 22:21
NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The approval is based on data from electronic health records and postmarketin
Thu Apr 04, 2019 21:57
OSAKA, Japon, AMSTERDAM, Pays-Bas et FLORHAM PARK, New Jersey--(BUSINESS WIRE)--Shionogi & Co, Ltd. (Siège social : Osaka, Japon ; Président et CEO : Isao Teshirogi, Ph.D.) et Shionogi B.V. et Shionogi Inc. les filiales européennes et américaines de Shionogi & Co, Ltd (ci-après "Shionogi") ont annoncé aujourd'hui 12 présentations de données qui auront lieu au Congrès européen de microbiologie clinique et maladies infectieuses (ECCMID), tenu du 13 au 16 avril 2019 à Amsterdam. Huit poste
Thu Apr 04, 2019 21:37
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Cook Biotech announced a new sales collaboration with Progressive Medical. Sales representatives employed by Progressive Medical will manage and support sales in the field for the Cook Biotech Biodesign Hernia Graft. Progressive Medical has sold and distributed products focused on overall cost effectiveness, efficiency, improved patient outcomes, and safety for over 33 years. "It is our mission and commitment to support improved outcomes, quality of care,
Thu Apr 04, 2019 21:24
OSAKA, Giappone, AMSTERDAM e FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Sede centrale: Osaka, Giappone; Presidente e CEO: Isao Teshirogi, Ph.D.) e Shionogi B.V. e Shionogi Inc., rispettivamente le affiliate europea e statunitense di Shionogi & Co., Ltd, (d'ora in avanti "Shionogi") oggi hanno annunciato 12 presentazioni di dati nell'ambito dell'European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), che si svolgerà ad Amsterdam dal 13 al 16 aprile 20
Thu Apr 04, 2019 20:11
DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trial Packaging Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global Clinical Trial Packaging Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include rising importance of booklet labels, increasing emphasis on the research and development and advancements in mobile technologies. This industry
Thu Apr 04, 2019 19:16
DENVER--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/NASH?src=hash" target="_blank"gt;#NASHlt;/agt;--HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending blood-based technology for evaluating the function of the liver, today announced the results from its proprietary HepQuant SHUNT™ Liver Diagnostic Kit in INTERCEPT's placebo-controlled clinical trial of obeticholic acid (OCA), 747-117. The HepQuant DSI results from the trial will be presented...
Thu Apr 04, 2019 19:00
FRANCFORT, Allemagne--(BUSINESS WIRE)--Merz, leader mondial de l'esthétique et des neurotoxines, a annoncé aujourd'hui que des données cliniques sur l'utilisation du portefeuille de Merz Aesthetics (Belotero®, Cellfina®, Radiesse®, Ultherapy® et la toxine botulique), feront l'objet de présentations orales et par affiches à l'occasion de l'édition 2019 du Congrès mondial de la médecine esthétique et anti-âge (AMWC), qui se tiendra du jeudi 4 au samedi 6 avril 2019 à Monte-Carlo (Monaco). En plus
Thu Apr 04, 2019 18:54
FRANCOFORTE, Germania--(BUSINESS WIRE)--Merz, leader globale nella medicina estetica e nelle neurotossine, ha oggi annunciato che illustrerà dati clinici sull'utilizzo del portafoglio di Merz Aesthetics, inclusi Belotero®, Cellfina®, Radiesse®, Ultherapy® e la tossina botulinica, nel corso di presentazioni orali e poster al 2019 Aesthetic & Anti-Aging Medicine World Congress (AMWC), che si svolgerà da giovedì 4 aprile a sabato 6 aprile 2019 a Monte Carlo, nel Principato di Monaco. Oltre all
Thu Apr 04, 2019 18:54
MALVERN, Pa.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/antibiotics?src=hash" target="_blank"gt;#antibioticslt;/agt;--Dr. Lisa Wittmer has 20+ years experience in global regulatory affairs along with developing, licensing and commercializing new therapeutics.
Thu Apr 04, 2019 18:00
PALM SPRINGS, Calif. & SCHLIEREN, Suiza--(BUSINESS WIRE)--Los investigadores clínicos podrán ser capaces de medir y cuantificar directamente miles de proteínas de los tejidos de los pacientes en los ensayos clínicos utilizando tecnología proteómica de próxima generación libre de etiquetas desarrollada por Biognosys, una empresa de proteómica Suiza. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser compara
Thu Apr 04, 2019 17:55
GREENSBORO, N.C.--(BUSINESS WIRE)--Karl Stonecipher, MD at Physicians Protocol, is participating in the AcuFocus clinical study for the IC-8 intraocular lens designed for cataracts.
Thu Apr 04, 2019 16:05
OSAKA, Japan & AMSTERDAM, Netherlands & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi announced 12 data presentations taking place at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Thu Apr 04, 2019 16:00
DUBLIN--(BUSINESS WIRE)--The "Alpha-Mannosidosis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Alpha-Mannosidosis Global Clinical Trials Review, H2, 2018" provides an overview of Alpha-Mannosidosis clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha-Mannosidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. T
Thu Apr 04, 2019 15:54
FRANKFURT, Duitsland--(BUSINESS WIRE)--Merz, een wereldleider in esthetica en neurotoxinen, heeft vandaag aangekondigd dat klinische gegevens over het gebruik van de Merz Aesthetics portfolio, waaronder Belotero®, Cellfina®, Radiesse®, Ultherapy® en Botulinum Toxin te zien zijn in mondelinge en poster presentaties op het Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2019, dat wordt gehouden van donderdag 4 april tot zaterdag 6 april 2019 in Monte-Carlo, Monaco. Naast de onderstaande
Thu Apr 04, 2019 15:44
FRÁNCFORT, Alemania--(BUSINESS WIRE)--Merz, líder mundial en medicina estética y neurotoxinas, ha anunciado hoy que los datos clínicos sobre el uso de la cartera de productos de medicina estética de Merz, que incluye Belotero®, Cellfina®, Radiesse®, Ultherapy® y la toxina botulínica, se darán a conocer en distintas presentaciones orales y pósters en el congreso mundial de medicina estética y antienvejecimiento (Aesthetic & Anti-Aging Medicine World Congress, AMWC) de 2019, que se tendrá lug
Thu Apr 04, 2019 15:33
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology expanded two more cohorts from the P II SUMMIT trial investigating neratinib in patients with activating EGFR or HER2 mutations.
Thu Apr 04, 2019 15:30
OSAKA, Japan, AMSTERDAM, & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co. (hoofdkantoor: Osaka, Japan; President en CEO: Isao Teshirogi, Ph.D.) en Shionogi B.V. en Shionogi Inc., de Europese en Amerikaanse dochterondernemingen van respectievelijk Shionogi & Co., Ltd. (hierna "Shionogi") hebben vandaag 12 presentaties aangekondigd die plaatsvinden op het European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), dat op 13-16 april 2019 in Amsterdam plaatsvindt. Ach
Thu Apr 04, 2019 15:28
OSAKA, Japón, ÁMSTERDAM y FLORHAM PARK, Nueva Jersey--(BUSINESS WIRE)--Shionogi & Co., Ltd. (sede: Osaka, Japón; presidente y CEO: Isao Teshirogi, Ph.D.) y Shionogi BV y Shionogi Inc., filiales europea y estadounidense de Shionogi & Co., Ltd respectivamente, (en adelante, "Shionogi") han anunciado hoy 12 presentaciones de datos que se llevarán a cabo en el Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas (European Congress of Clinical Microbiology and Infectious Dise
Thu Apr 04, 2019 15:25
Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval
DANVERS, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/heartrecovery?src=hash" target="_blank"gt;#heartrecoverylt;/agt;--Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval
Thu Apr 04, 2019 15:11
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, April 25, 2019 1:30 p.m. Pacific Time / 4:30 p.m. Eastern T
Thu Apr 04, 2019 15:00
PALM SPRINGS, Calif. & SCHLIEREN, Switzerland--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MSACL?src=hash" target="_blank"gt;#MSACLlt;/agt;--Roche suggests that discovery proteomics might soon move into the clinical trial setting, in a recent mock study using Biognosys' data.
Fri Apr 05, 2019 11:01
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc., a privately held, clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's disease (AD) and other degenerative diseases, today announced the election of veteran biopharma finance executive Christopher J. Senner to the company's Board of Directors. "Chris Senner's deep financial expertise, gained at some of our industry's most notable companies,
Thu Apr 04, 2019 15:00
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 25, 2019 to discuss its first quarter 2019 financial results. The call may be accessed through an operator by calling (844) 884-9951 for dom
Thu Apr 04, 2019 15:00
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer, Frederic Ors will be making an investor presentation at the 2019 Bloom Burton & Co Healthcare Investor Conference, which will be held from April 30 to May 1, 2019 in Toronto, Ontario. IMV's presentation details include: Date: Wednesday, May 1, 2019 Time: 11:00 a.m. ET Location: Metro Toronto Convention Centre, 255 Front St W, T
Thu Apr 04, 2019 14:05
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the full two-year outcomes from its U.S. Investigational Device Exemption (IDE) study of the M6-C™ artificial cervical disc. Dr. Jack Zigler, orthopedic spine surgeon at Texas Back Institute and an investigator in the study, presented the study results during the International Society for the Advancement of Spine Surgery (ISA
Thu Apr 04, 2019 14:00
LAUSANNE, Switzerland--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/bloodtests?src=hash" target="_blank"gt;#bloodtestslt;/agt;--Loop Medical gets second grant from Bill and Melinda Gates Foundation to support pre-production and clinical trials of novel blood collection device.
Thu Apr 04, 2019 14:00
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced that its marketed product UriVarx® has received approval for an expanded claim to include "helps improve the symptoms of urinary incontinence." Inn
Thu Apr 04, 2019 13:00
OSAKA, Japon et AMSTERDAM, Pays-Bas--(BUSINESS WIRE)--Shionogi & Co, Ltd. et sa filiale européenne, Shionogi B.V. (ci-après "Shionogi"), a annoncé qu'elle présentera quatre posters sur le Lusutrombopag, un agoniste des récepteurs de la thrombopoïétine (TPO) à petites molécules à administration orale unique quotidienne, lors du International Liver Congress™, la réunion annuelle de l'Association Européenne pour l'Étude du Foie (EASL), qui se tiendra à Vienne, Autriche du 10 au 14 avril 2019.
Thu Apr 04, 2019 12:58
OSAKA, Japan & AMSTERDAM, NL--(BUSINESS WIRE)--Shionogi & Co., Ltd. en haar Europese dochteronderneming, Shionogi B.V. (hierna "Shionogi"), kondigde aan dat het vier posters zal presenteren op lusutrombopag, een eenmaal daags, mondeling toegediende, kleine moleculaire trombopoïetine (TPO) receptor agonist, op het International Liver Congress™, de jaarlijkse bijeenkomst van de European Association for the Study of the Liver (EASL), die zal worden gehouden in Wenen, Oostenrijk, 10-14 april...
Thu Apr 04, 2019 12:50
OSAKA, Japón y ÁMSTERDAM, Países Bajos--(BUSINESS WIRE)--Shionogi & Co., Ltd. y su filial europea, Shionogi BV (en adelante, "Shionogi"), han anunciado que presentarán cuatro pósters sobre lusutrombopag, un agonista del receptor de trombopoyetina (TPO) de molécula pequeña administrado por vía oral una vez al día, en el International Liver Congress™, el congreso anual de la Asociación Europea para el Estudio del Hígado (EASL, European Association for the Study of the Liver), que se celebrará
Thu Apr 04, 2019 12:43
FRANKFURT, Deutschland--(BUSINESS WIRE)--Merz, einer der weltweit führenden Anbieter im Bereich Ästhetik und Neurotoxine, gab heute bekannt, dass das Unternehmen auf dem Aesthetic & Anti-Aging Medicine World Congress (AMWC) die neuesten klinischen Daten zur Verwendung des Portfolios von Merz Aesthetics präsentieren wird. Die Daten zum Portfolio, das die Produkte Belotero®, Cellfina®, Radiesse®, Ultherapy® und Botulinum Toxin umfasst, werden vom 04. April bis 6.April 2019 in Monte-Carlo, Mon
Thu Apr 04, 2019 11:20
FRANKFURT, Germany--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AMWC2019?src=hash" target="_blank"gt;#AMWC2019lt;/agt;--Merz, a global leader in aesthetics and neurotoxins, announced today that clinical data on the use of the Merz Aesthetics portfolio, including Belotero®, Cellfina®, Radiesse®, Ultherapy® and Botulinum Toxin will be featured in oral and poster presentations at the 2019 Aesthetic & Anti-Aging Medicine World Congress (AMWC), to be held from Thursday, April 4 to Saturday,...
Thu Apr 04, 2019 11:19
Click image to enlarge The SELECT Study is being done to see if semaglutide can reduce the risk of cardiovascular events such as heart attack or stroke. Previous studies of semaglutide have shown that using semaglutide reduced the risk of cardiovascular events in some people with type 2 diabetes. Semaglutide is already approved in some countries at a lower dose, to treat type 2 diabetes. The SELECT study will examine the effect of semaglutide in people with established cardiovascular disease and...
Fri Apr 05, 2019 00:00
Click image to enlargeCentanafadine is a non-stimulant, triple reuptake inhibitor that modulates norepinephrine, dopamine and serotonin reuptake with the intent of improving focus, attention, and specific higher level cognitive skills in patients with ADHD. Two phase II clinical trials in adults, including a phase IIb trial, have been completed for centanafadine, setting the stage for the start of phase III trials in ADHD. It can take up to 28 days for your study doctor to confirm you are eligible...
Fri Apr 05, 2019 00:00
Do you have acne? You may be a candidate for our clinical research study!We are currently enrolling qualified participants in a clinical research study for an investigational topical cream.If you are interested in participating in our Acne study, please fill out the form below.
Fri Apr 05, 2019 00:00
it is a Actinic keratosis. Participants Must have minimum of 5 to 10 Ak lisions.
Thu Apr 04, 2019 00:00
Trouble getting around because of hip or knee pain? Do you suffer from hip or knee pain, stiffness and swelling related to arthritis? Paid research studies in your area are now enrolling. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right now, doctors are looking for people with hip or knee pain from arthritis to volunteer for local research studies. * In a clinical research study, the participants...
Thu Apr 04, 2019 00:00
Research study needs volunteers with ulcerative colitis A clinical research study is enrolling people with ulcerative colitis who have tried medication but still have moderate to severe symptoms. Volunteer for this study and you may receive: Compensation Study-related medical care * In a clinical research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from...
Thu Apr 04, 2019 00:00
Have heart disease? Do you or a loved one have heart disease with high cholesterol? If so, you may qualify for local research studies testing a study medication not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right now, doctors are looking for people with heart disease to volunteer for local heart health research studies. * In a clinical research study, the...
Thu Apr 04, 2019 00:00
Research study needs people with atopic dermatitis Have you or a loved one been living with atopic dermatitis (a chronic, recurring, inflammatory, and itchy skin condition) for 2 years or more? If so, you (or they) may qualify for a clinical research study, which is currently testing an investigational topical cream for atopic dermatitis. Those who qualify and participate in this study may receive: Study-related care from local doctors Investigational study medication Participants must be 18...
Thu Apr 04, 2019 00:00
Do you or a loved one have Endometriosis? Does Endometriosis prevent you from living life to its fullest? If so, you may qualify for local research studies. Right now, local doctors are looking for women with Endometriosis to join local research studies. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right now, doctors are looking for women with Endometriosis to volunteer for local research...
Thu Apr 04, 2019 00:00
STAMFORD, Conn. – March 28, 2019 – Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, today announced that the U.S. Food and...
Thu Mar 28, 2019 08:04
OXFORD, England & CONSHOHOCKEN, Pa.--April 03, 2019 --Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its...
Thu Apr 04, 2019 08:04
The US Department of Justice (DOJ) alleged that the three pharmaceutical firms have violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical The post Three pharma firms agree to pay $122.6m to settle kickback allegations appeared first on Pharmaceutical Business review.
Fri Apr 05, 2019 12:11
The cohorts that have been expanded are (i) HER2 mutant patients with metastatic salivary gland cancer and (ii) patients with EGFR exon 18 mutation-positive lung cancer. The Phase The post Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib appeared first on Pharmaceutical Business review.
Fri Apr 05, 2019 12:11
Under the terms of the agreement, LakePharma will have the ability to offer Twist's proprietary antibody discovery and optimization platforms to their existing and future biopharmaceutical customers as The post Twist Bioscience and LakePharma form strategic collaboration to provide antibody discovery and development services appeared first on Pharmaceutical Business review.
Fri Apr 05, 2019 12:11
The approval was based on data from Archer 1050 randomized, multicenter, multinational and open-label phase 3 study conducted in patients with unresectable, metastatic or recurrent NSCLC harboring EGFR The post Pfizer gets EC approval for Vizimpro lung cancer monotherapy appeared first on Pharmaceutical Business review.
Thu Apr 04, 2019 15:41
Pegfilgrastim is a long-acting version of filgrastim and may be prescribed to appropriate cancer patients undergoing chemotherapy to enhance the production of infection-fighting white blood cells2. Studies have The post Sandoz resubmits biosimilar pegfilgrastim application to US FDA appeared first on Pharmaceutical Business review.
Thu Apr 04, 2019 11:34
These results were presented at the 25th Annual Conference of the British HIV Association (BHIVA) taking place from 2-5 April in Bournemouth, UK. Professor Chloe Orkin, Consultant Physician The post ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks appeared first on Pharmaceutical Business review.
Thu Apr 04, 2019 11:34
Publication date: Available online 5 April 2019Source: Contemporary Clinical TrialsAuthor(s): Paula P. Schnurr, Kathleen M. Chard, Josef I. Ruzek, Bruce K. Chow, Mei-Chiung Shih, Patricia A. Resick, Edna B. Foa, Brian P. Marx, Grant D. Huang, Ying Lu
Sat Apr 06, 2019 16:35
Publication date: Available online 4 April 2019Source: Contemporary Clinical TrialsAuthor(s): Joseph D. Harrison, Jeremy M. Jones, Dylan S. Small, Charles A.L. Rareshide, Gregory Szwartz, David Steier, James Guszcza, Pameljit Kalra, Brian Torio, Gregory Reh, Victoria Hilbert, Mitesh S. PatelAbstractBackgroundLess than half of adults in the United States (US) obtain the recommended level of physical activity. Social incentives, the influences that impact individuals to adjust their behaviors based...
Fri Apr 05, 2019 14:33
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου